Entry Point Capital, LLC Travere Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $246 Million
- Q3 2025
A detailed history of Entry Point Capital, LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 12,101 shares of TVTX stock, worth $417,484. This represents 0.12% of its overall portfolio holdings.
Number of Shares
12,101
Previous 18,438
34.37%
Holding current value
$417,484
Previous $272,000
6.25%
% of portfolio
0.12%
Previous 0.14%
Shares
5 transactions
Others Institutions Holding TVTX
# of Institutions
269Shares Held
100MCall Options Held
2.36MPut Options Held
955K-
Janus Henderson Group PLC London, X010.6MShares$366 Million0.12% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$264 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY6.72MShares$232 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.61MShares$228 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.98MShares$172 Million0.14% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $2.21B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...